1
|
Skeie BS, Enger PØ, Knisely J, Pedersen PH, Heggdal JI, Eide GE, Skeie GO. A simple score to estimate the likelihood of pseudoprogression vs. recurrence following stereotactic radiosurgery for brain metastases: The Bergen Criteria. Neurooncol Adv 2020; 2:vdaa026. [PMID: 32642686 PMCID: PMC7212847 DOI: 10.1093/noajnl/vdaa026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background A major challenge in the follow-up of patients treated with stereotactic radiosurgery (SRS) for brain metastases (BM) is to distinguish pseudoprogression (PP) from tumor recurrence (TR). The aim of the study was to develop a clinical risk assessment score. Methods Follow-up images of 87 of 97 consecutive patients treated with SRS for 348 BM were analyzed. Of these, 100 (28.7%) BM in 48 (53.9%) patients responded with either TR (n = 53, 15%) or PP (n = 47, 14%). Differences between the 2 groups were analyzed and used to develop a risk assessment score (the Bergen Criteria). Results Factors associated with a higher incidence of PP vs. TR were as follows: prior radiation with whole brain radiotherapy or SRS (P = .001), target cover ratio ≥98% (P = .048), BM volume ≤2 cm3 (P = .054), and primary lung cancer vs. other cancer types (P = .084). Based on the presence (0) or absence (1) of these 5 characteristics, the Bergen Criteria was established. A total score <2 points was associated with 100% PP, 2 points with 57% PP and 43% TR, 3 points with 57% TR and 43% PP, whereas >3 points were associated with 84% TR and 16% PP, P < .001. Conclusion Based on 5 characteristics at the time of SRS the Bergen Criteria could robustly differentiate between PP vs. TR following SRS. The score is user-friendly and provides a useful tool to guide the decision making whether to retreat or observe at appropriate follow-up intervals.
Collapse
Affiliation(s)
| | - Per Øyvind Enger
- Department of Neurosurgery, Stavanger University Hospital, Stavanger, Norway
| | - Jonathan Knisely
- Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
| | | | - Jan Ingeman Heggdal
- Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway
| | - Geir Egil Eide
- Department of Global Public Health and Primary Care, University of Bergen, Norway.,Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway
| | - Geir Olve Skeie
- Department of Neurology, Haukeland University Hospital, Bergen, Norway
| |
Collapse
|
2
|
Dzialo CM, Pedersen PH, Jensen KK, de Zee M, Andersen MS. Evaluation of predicted patellofemoral joint kinematics with a moving-axis joint model. Med Eng Phys 2019; 73:85-91. [PMID: 31474509 DOI: 10.1016/j.medengphy.2019.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 07/27/2019] [Accepted: 08/15/2019] [Indexed: 10/26/2022]
Abstract
The main objectives of this study were to expand the moving-axis joint model concept to the patellofemoral joint and evaluate the patellar motion against experimental patellofemoral kinematics. The experimental data was obtained through 2D-to-3D bone reconstruction of EOS images and segmented MRI data utilizing an iterative closest point optimization technique. Six knee model variations were developed using the AnyBody Modeling System and subject-specific bone geometries. These models consisted of various combinations of tibiofemoral (hinge, moving-axis, and interpolated) and patellofemoral (hinge and moving-axis) joint types. The newly introduced interpolated tibiofemoral joint is calibrated from the five EOS quasi-static lunge positions. The patellofemoral axis of the hinge model was defined by performing surface fits to the patellofemoral contact area; and the moving-axis model was defined based upon the position of the patellofemoral joint at 0° and 90° tibiofemoral-flexion. In between these angles, the patellofemoral axis moved linearly as a function of tibiofemoral-flexion, while outside these angles, the axis remained fixed. When using a moving-axis tibiofemoral joint, a hinge patellofemoral joint offers (-5.12 ± 1.23 mm, 5.81 ± 0.97 mm, 14.98 ± 2.30°, -4.35 ± 1.95°) mean differences (compared to EOS) while a moving-axis patellofemoral model provides (-2.69 ± 1.04 mm, 1.13 ± 0.80 mm, 12.63 ± 2.03°, 1.74 ± 1.46°) in terms of lateral-shift, superior translation, patellofemoral-flexion, and patellar-rotation, respectively. Furthermore, the model predictive capabilities increased as a direct result of adding more calibrated positions to the tibiofemoral model (hinge-1, moving-axis-2, and interpolated-5). Overall, a novel subject-specific moving-axis patellofemoral model has been established; that produces realistic patellar motion and is computationally fast enough for clinical applications.
Collapse
Affiliation(s)
- C M Dzialo
- AnyBody Technology, A/S Niels Jernes Vej 10, DK 9220 Aalborg, Denmark; Department of Materials and Production, Aalborg University, Fibigerstræde 16, DK-9220 Aalborg, Denmark.
| | - P H Pedersen
- Department of Orthopedic Surgery, Aalborg University Hospital, Hobrovej 18-22, DK-9000 Aalborg, Denmark
| | - K K Jensen
- Department of Radiology, Aalborg University Hospital, Hobrovej 18-22, DK-9000 Aalborg, Denmark
| | - M de Zee
- Department of Health Science and Technology, Sport Sciences, Aalborg University, Fredrik Bajers Vej 7D, DK-9220 Aalborg, Denmark
| | - M S Andersen
- Department of Materials and Production, Aalborg University, Fibigerstræde 16, DK-9220 Aalborg, Denmark
| |
Collapse
|
3
|
Skeie BS, Enger PØ, Pedersen PH, Skeie GO. RADI-23. CLINICAL RISK ASSESSMENT SCORE TO ESTIMATE THE LIKELIHOOD OF PSEUDOPROGRESSION VERSUS TUMOR RECURRENCE FOLLOWING STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES. Neurooncol Adv 2019. [PMCID: PMC7213319 DOI: 10.1093/noajnl/vdz014.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVE: A major challenge in the follow-up of patients managed with stereotactic radiosurgery (SRS) for brain metastases (BM) is to differentiate pseudoprogression (PP) from tumor recurrence (TR). A clinical score based on tumor and treatment related factors would be valuable when selecting appropriate treatment. MATERIAL AND METHODS: Follow-up images of 97 consecutive patients treated with SRS for 406 BM were analyzed. Of these 100 (24.6 %) BM in 48 (49.5 %) patients responded either with TR (delayed growth; 53 (13.1 %) BM) or PP (temporary volume increase; 47 (11.6 %) BM). Differences between the 2 groups were analyzed and used to develop a PP risk assessment score (PP-RAS). RESULTS: Significant factors associated with a higher incidence of PP versus TR were: primary lung cancer vs. other primaries, BM volume ≤ 2cc (or BM ≤ 1.5 cm in diameter), Target cover ratio > 98 % and prior radiation SRS or WBRT. Based on the presence (0) or not (1) of these 5 parameters, a risk assessment score for PP versus TR was established. A PP-RAS score of 0 corresponds with high likelihood of PP vs. TR, whereas a score of 5 corresponds with a high risk of TR. A score of ≤ 1 point was associated with 100 % PP, 2 points with 57 % PP and 43 % TR, 3 points with 57 % TR and 43 % PP, whereas ≥ 4 points were associated with 84 % TR and 16 % PP, π=24.57, df =4, p < 0.001). CONCLUSION: Based on these 5 parameters at the time of SRS our risk assessment score could robustly differentiate between PP versus growth following SRS. The score is user-friendly and may be a useful tool to guide the decision making whether to retreat or observe at appropriate follow-up intervals.
Collapse
|
4
|
Skeie B, Øyvind Enger P, Pedersen PH, Olve Skeie G. CMET-19. CLINICAL RISK ASSESSMENT SCORE TO ESTIMATE THE LIKELIHOOD OF PSEUDOPROGRESSION VERSUS TUMOR GROWTH FOLLOWING STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Bente Skeie
- Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway
| | | | | | - Geir Olve Skeie
- Department of Neurology, Haukeland University hospital, Bergen, Bergen, Norway
| |
Collapse
|
5
|
Bragstad S, Flatebø M, Natvig GK, Eide GE, Skeie GO, Behbahani M, Pedersen PH, Enger PØ, Skeie BS. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study. J Neurosurg 2018; 129:71-83. [DOI: 10.3171/2017.2.jns161659] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
OBJECTIVELung cancer (LC) patients who develop brain metastases (BMs) have a poor prognosis. Estimations of survival and risk of treatment-related deterioration in quality of life (QOL) are important when deciding on treatment. Although we know of several prognostic factors for LC patients with BMs, the role of QOL has not been established. Authors of this study set out to evaluate changes in QOL following Gamma Knife surgery (GKS) for BMs in LC patients and QOL as a prognostic factor for survival.METHODSForty-four of 48 consecutive LC patients with BMs underwent GKS in the period from May 2010 to September 2011, and their QOL was prospectively assessed before and 1, 3, 6, 9, and 12 months after GKS by using the Functional Assessment of Cancer Therapy–Brain (FACT-BR) questionnaire. A mixed linear regression model was used to identify potential predictive factors for QOL and to assess the effect of GKS and the disease course on QOL at follow-up.RESULTSMean QOL as measured by the brain cancer subscale (BRCS) of the FACT-BR remained stable from baseline (score 53.0) up to 12 months post-GKS (57.1; p = 0.624). The BRCS score improved for 32 patients (72.3%) with a total BM volume ≤ 5 cm3. Mean improvement in these patients was 0.45 points each month of follow-up, compared to a decline of 0.50 points each month despite GKS treatment in patients with BM volumes > 5 cm3 (p = 0.04). Asymptomatic BMs (p = 0.01), a lower recursive partitioning analysis (RPA) classification (p = 0.04), and a higher Karnofsky Performance Scale (KPS) score (p < 0.01) at baseline were predictors for a high, stable QOL after GKS. After multivariate analysis, a high KPS score (p < 0.01) remained the only positive predictor of a high, stable QOL post-GKS.Median survival post-GKS was 5.6 months (95% CI 1.0–10.3). A higher BRCS score (p = 0.01), higher KPS score (p = 0.01), female sex (p = 0.01), and the absence of liver (p = 0.02), adrenal (p = 0.02), and bone metastases (p = 0.03) predicted longer survival in unadjusted models. However, in multivariate analyses, a higher BRCS score (p < 0.01), female sex (p = 0.01), and the absence of bone metastases (p = 0.02) at GKS remained significant predictors. Finally, the BRCS score’s predictive value for survival was compared with the values for the variables behind well-known prognostic indices: age, KPS score, extracranial disease status, and number and volume of BMs. Both BRCS score (p = 0.01) and BM volume (p = 0.05) remained significant predictors for survival in the final model.CONCLUSIONSPatient-reported QOL according to the BRCS is a predictor of survival in patients with BMs and may be helpful in deciding on the optimal treatment. Gamma Knife surgery is a safe and effective therapeutic modality that improves QOL for LC patients with a BM volume ≤ 5 cm3 at treatment. Careful follow-up and salvage therapy on demand seem to prevent worsening of QOL due to relapse of BMs.
Collapse
Affiliation(s)
- Sidsel Bragstad
- Departments of 1Neurosurgery,
- 2Department of Global Public Health and Primary Care
| | | | | | - Geir Egil Eide
- 2Department of Global Public Health and Primary Care
- 4Centre for Clinical Research, Haukeland University Hospital
| | | | - Maziar Behbahani
- Departments of 1Neurosurgery,
- 6Department of Neurosurgery, Stavanger University Hospital, Stavanger, Norway
| | | | - Per Øyvind Enger
- Departments of 1Neurosurgery,
- 8Oncomatrix, Institute of Biomedicine, University of Bergen; and
| | | |
Collapse
|
6
|
Skeie BS, Eide GE, Flatebø M, Heggdal JI, Larsen E, Bragstad S, Pedersen PH, Enger PØ. Quality of life is maintained using Gamma Knife radiosurgery: a prospective study of a brain metastases patient cohort. J Neurosurg 2017; 126:708-725. [DOI: 10.3171/2015.10.jns15801] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
OBJECTIVE
Gamma Knife radiosurgery (GKRS) is increasingly used in the management of brain metastases (BMs), but few studies have evaluated how GKRS impacts quality of life (QOL). The aim of this study was to monitor QOL as the primary end point following GKRS in a patient cohort with BM.
METHODS
The study included 97 consecutive patients with 1–6 BMs treated with GKRS between May 2010 and September 2011. QOL was assessed at baseline and at 1, 3, 6, 9, and 12 months postoperatively using the Functional Assessment of Cancer Therapy–Brain (FACT-BR) questionnaire with the brain cancer subscale (BRCS) questionnaire. Factors predicting QOL were identified by mixed linear regression analyses. Local control and toxicity were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) and the European Organisation for Research and Treatment/Radiation Therapy Oncology Group (EORTC/RTOG) criteria of late effects, respectively.
RESULTS
Compliance was high from baseline (97%) to 12-month follow-up (78%). Mean BRCS scores remained high during follow-up: they improved in 66% of patients and remained unchanged in 6% at 9 months. Local control (p = 0.018), improved symptoms (p = 0.005), and stable extracerebral disease (p = 0.001) correlated with high QOL-BRCS score. High baseline recursive partitioning analysis class predicted improved QOL (p = 0.031), whereas high Karnofsky Performance Scale score (p = 0.017), asymptomatic BMs (p = 0.001), and no cognitive deficits (p = 0.033) or seizures (p = 0.040) predicted high, stable QOL-BRCS during the 12-month follow-up.
CONCLUSIONS
QOL remained stable for up to 12 months following GKRS for the total cohort. High QOL was reported if local control occurred, cerebral symptoms improved/stabilized, or the need for steroids declined, which all reflected successful GKRS. Conversely, low QOL accompanied progression of intra- and extracerebral disease. Based on the study findings, GKRS appears to be a safe and effective treatment option for patients with BMs.
Collapse
Affiliation(s)
| | - Geir Egil Eide
- 5Global Public Health and Primary Care, University of Bergen, Norway
- 6Centre for Clinical Research, Haukeland University Hospital; and
| | | | | | | | | | | | - Per Øyvind Enger
- Departments of 1Neurosurgery and
- 3Biomedicine, Oncomatrix Research Lab, and
| |
Collapse
|
7
|
Førde HE, Sleire L, Espedal H, Heggdal JI, Selheim F, Pedersen PH, Enger PØ. Abstract 3048: Drug repurposing: Validation of sulfasalazine as a radiosensitizer in melanoma by blocking system Xc−. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-3048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Melanoma is a cancer that has become increasingly frequent over the last decades in the western world. Initial treatment for primary and locoregional melanoma is surgery. In metastatic disease, systematic treatment and recently immunotherapy has been the mainstay. At this stage however, the prognostic outlook is still bleak. Thus, new treatments are urgently needed.
Melanoma is considered to be a radioresistant cancer. The mechanisms underlying radioresistance are multiple and incompletely characterized. In some tumors, radioresistance is mediated by increased synthesis of anti-oxidants that scavenge reactive oxygen species (ROS), induced by radiotherapy. Glutathione (GSH) is an anti-oxidant synthesized from cystine and constitutes a major defense system against oxidative stress in mammalian cells. Cystine is taken up through system Xc− (SXC), an anti-port transmembrane protein with catalytic subunit xCT. Sulfasalazine, a drug approved in the 1950s for treatment of rheumatoid arthritis and inflammatory bowel disease, has been shown to block SXC. Based on previous reports by others, and our own recent findings, we hypothesize that: I) xCT represents a mechanism for radioresistance and is expressed in radioresistant melanoma cancer and II) xCT inhibitors can act as radiosensitizers to potentiate the efficacy of radiotherapy. Expression of the catalytic subunit of SXC, xCT, was found in tissue micro array of primary and secondary melanoma biopsies. In addition, SAS treatment dramatically reduced cystine-uptake and GSH levels in melanoma cells in vitro, and markedly increased the levels of reactive oxygen species (ROS). Furthermore, SAS and radiation synergistically increased DNA double-strand breaks and increased glioma cell death, whereas adding the anti-oxidant N-acetyl-L-cysteine (NAC) reversed cell death. Moreover, SAS and irradiation synergistically reduced subcutaneous melanoma tumor growth in vivo, compared to controls or either treatment alone. Thus, future experimental studies are warranted to validate SAS as a radiosensitizer in the treatment of metastatic melanoma. Future studies will also be aimed at assessing the effect on pulmonary melanoma metastasis.
Citation Format: Hilde Elise Førde, Linda Sleire, Heidi Espedal, Jan Ingemann Heggdal, Frode Selheim, Paal-Henning Pedersen, Per Øyvind Enger. Drug repurposing: Validation of sulfasalazine as a radiosensitizer in melanoma by blocking system Xc−. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3048.
Collapse
Affiliation(s)
- Hilde Elise Førde
- 1Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Linda Sleire
- 1Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Heidi Espedal
- 2Department of Biomedicine, Molecular Imaging Center (MIC), University of Bergen, Bergen, Norway
| | - Jan Ingemann Heggdal
- 3Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway
| | - Frode Selheim
- 4Department of Biomedicine, Proteomics Unit (Probe), University of Bergen, Bergen, Norway
| | - Paal-Henning Pedersen
- 5Department of Clinical Medicine, K1, University of Bergen, Bergen, Norway; Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway
| | - Per Øyvind Enger
- 6Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, Bergen, Norway; Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway
| |
Collapse
|
8
|
Sleire L, Skeie BS, Netland IA, Førde HE, Dodoo E, Selheim F, Leiss L, Wang J, Heggdal J, Pedersen PH, Enger PØ. Abstract 1789: Drug repurposing: Sulfasalazine sensitizes gliomas to gamma knife surgery by blocking cystine uptake through System XC−, leading to gluthatione depletion. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-1789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Glioblastomas (GBMs) are lethal cancers and inherently resistant to radiotherapy. Established treatments including surgery, radio- and chemotherapy have a limited efficacy, and the median survival is approximately 14.6 months. Thus, treatment resistance represents a major challenge in the clinical management of these patients, and new therapies are urgently needed.
We hypothesized that the Xc−-inhibitor sulfasalazine (SAS) could potentiate the efficacy of radiotherapy against gliomas. Expression of the catalytic subunit of system Xc−, xCT, was found in a panel of 30 human GBM biopsies. Sections from normal brain tissue displayed only weak immunopositivity, thus our findings therefore suggest that xCT expression is common to most GBMs, which together with its low expression in normal brain tissue could provide a therapeutic window. SAS treatment dramatically reduced cysteine-uptake and glutathione (GSH) levels in glioma cells in vitro and markedly increased the levels of reactive oxygen species (ROS). Furthermore, SAS and radiation synergistically increased DNA double-strand breaks and increased glioma cell death, whereas adding the antioxidant N-acetyl-L-cysteine (NAC) reversed cell death. Moreover, SAS and gamma knife radiosurgery (GKRS) synergistically prolonged survival in nude rats harboring human GBM xenografts, compared to controls or either treatment alone. In conclusion, SAS effectively blocks cystine uptake in glioma cells in vitro, leading to GSH depletion and increased ROS levels, DNA damage and cell death. Moreover, it potentiates the anti-tumor efficacy of GKRS in rats with human GBM xenografts, providing a survival benefit. Thus, SAS may have a role as a radiosensitizer to enhance the efficacy of current radiotherapies for glioma patients. We are currently preparing a clinical trial for patients with GBM recurrences combining pre-treatment with SAS and GKRS.
Citation Format: Linda Sleire, Bente Sandvei Skeie, Inger Anne Netland, Hilde Elise Førde, Ernest Dodoo, Frode Selheim, Lina Leiss, Jian Wang, Jan Heggdal, Paal-Henning Pedersen, Per Øyvind Enger. Drug repurposing: Sulfasalazine sensitizes gliomas to gamma knife surgery by blocking cystine uptake through System XC−, leading to gluthatione depletion. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1789. doi:10.1158/1538-7445.AM2015-1789
Collapse
Affiliation(s)
- Linda Sleire
- 1Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, Bergen, Norway
| | | | - Inger Anne Netland
- 1Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Hilde Elise Førde
- 1Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Ernest Dodoo
- 3Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden
| | - Frode Selheim
- 4Proteomics Unit (PROBE), Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Lina Leiss
- 1Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Jian Wang
- 1Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Jan Heggdal
- 5Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway
| | | | - Per Øyvind Enger
- 1Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, Bergen, Norway
| |
Collapse
|
9
|
Carlson ML, Tveiten OV, Driscoll CL, Goplen FK, Neff BA, Pollock BE, Tombers NM, Castner ML, Finnkirk MK, Myrseth E, Pedersen PH, Lund-Johansen M, Link MJ. Long-term quality of life in patients with vestibular schwannoma: an international multicenter cross-sectional study comparing microsurgery, stereotactic radiosurgery, observation, and nontumor controls. J Neurosurg 2015; 122:833-42. [DOI: 10.3171/2014.11.jns14594] [Citation(s) in RCA: 144] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECT
The optimal treatment for sporadic vestibular schwannoma (VS) is highly controversial. To date, the majority of studies comparing treatment modalities have focused on a narrow scope of technical outcomes including facial function, hearing status, and tumor control. Very few publications have investigated health-related quality of life (HRQOL) differences between individual treatment groups, and none have used a disease-specific HRQOL instrument.
METHODS
All patients with sporadic small- to medium-sized VSs who underwent primary microsurgery, stereotactic radiosurgery (SRS), or observation between 1998 and 2008 were identified. Subjects were surveyed via postal questionnaire using the 36-Item Short Form Health Survey (SF-36), the 10-item Patient-Reported Outcomes Measurement Information System short form (PROMIS-10), the Glasgow Benefit Inventory (GBI), and the Penn Acoustic Neuroma Quality-of-Life (PANQOL) scale. Additionally, a pool of general population adults was surveyed, providing a nontumor control group for comparison.
RESULTS
A total of 642 respondents were analyzed. The overall response rate for patients with VS was 79%, and the mean time interval between treatment and survey was 7.7 years. Using multivariate regression, there were no statistically significant differences between management groups with respect to the PROMIS-10 physical or mental health dimensions, the SF-36 Physical or Mental Component Summary scores, or the PANQOL general, anxiety, hearing, or energy subdomains. Patients who underwent SRS or observation reported a better total PANQOL score and higher PANQOL facial, balance, and pain subdomain scores than the microsurgical cohort (p < 0.02). The differences in scores between the nontumor control group and patients with VS were greater than differences observed between individual treatment groups for the majority of measures.
CONCLUSIONS
The differences in HRQOL outcomes following SRS, observation, and microsurgery for VS are small. Notably, the diagnosis of VS rather than treatment strategy most significantly impacts quality of life. Understanding that a large number of VSs do not grow following discovery, and that intervention does not confer a long-term HRQOL advantage, small- and medium-sized VS should be initially observed, while intervention should be reserved for patients with unequivocal tumor growth or intractable symptoms that are amenable to treatment. Future studies assessing HRQOL in VS patients should prioritize use of validated disease-specific measures, such as the PANQOL, given the significant limitations of generic instruments in distinguishing between treatment groups and tumor versus nontumor subjects.
Collapse
Affiliation(s)
| | | | - Colin L. Driscoll
- Departments of 1Otolaryngology-Head and Neck Surgery and
- 2Neurologic Surgery, Mayo Clinic School of Medicine, Rochester, Minnesota;
| | - Frederik K. Goplen
- 4Otolaryngology-Head and Neck Surgery, Haukeland University Hospital, Bergen; and
| | - Brian A. Neff
- Departments of 1Otolaryngology-Head and Neck Surgery and
| | - Bruce E. Pollock
- 2Neurologic Surgery, Mayo Clinic School of Medicine, Rochester, Minnesota;
| | | | - Marina L. Castner
- 2Neurologic Surgery, Mayo Clinic School of Medicine, Rochester, Minnesota;
| | | | | | - Paal-Henning Pedersen
- Departments of 3Neurosurgery and
- 5Department of Clinical Medicine, University of Bergen, Norway
| | - Morten Lund-Johansen
- Departments of 3Neurosurgery and
- 5Department of Clinical Medicine, University of Bergen, Norway
| | - Michael J. Link
- Departments of 1Otolaryngology-Head and Neck Surgery and
- 2Neurologic Surgery, Mayo Clinic School of Medicine, Rochester, Minnesota;
| |
Collapse
|
10
|
Sandvei Skeie B, Wang J, Dodoo E, Heggdal JI, Grønli J, Sleire L, Bragstad S, Ganz JC, Chekenya M, Mørk S, Pedersen PH, Enger PØ. Gamma knife surgery as monotherapy with clinically relevant doses prolongs survival in a human GBM xenograft model. Biomed Res Int 2013; 2013:139674. [PMID: 24312904 PMCID: PMC3842058 DOI: 10.1155/2013/139674] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/20/2013] [Revised: 09/17/2013] [Accepted: 09/19/2013] [Indexed: 11/18/2022]
Abstract
OBJECT Gamma knife surgery (GKS) may be used for recurring glioblastomas (GBMs). However, patients have then usually undergone multimodal treatment, which makes it difficult to specifically validate GKS independent of established treatments. Thus, we developed an experimental brain tumor model to assess the efficacy and radiotoxicity associated with GKS. METHODS GBM xenografts were implanted intracerebrally in nude rats, and engraftment was confirmed with MRI. The rats were allocated to GKS, with margin doses of 12 Gy or 18 Gy, or to no treatment. Survival time was recorded, tumor sections were examined, and radiotoxicity was evaluated in a behavioral open field test. RESULTS In the first series, survival from the time of implantation was 96 days in treated rats and 72 days in controls (P < 0.001). In a second experiment, survival was 72 days in the treatment group versus 54 days in controls (P < 0.006). Polynuclear macrophages and fibrosis was seen in groups subjected to GKS. Untreated rats with GBM xenografts displayed less mobility than GKS-treated animals in the open field test 4 weeks after treatment (P = 0.04). CONCLUSION GKS administered with clinically relevant doses prolongs survival in rats harboring GBM xenografts, and the associated toxicity is mild.
Collapse
Affiliation(s)
- Bente Sandvei Skeie
- Department of Neurosurgery, Haukeland University Hospital, 5021 Bergen, Norway
- Institute of Surgical Sciences, Haukeland University Hospital, 5021 Bergen, Norway
- Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, 5021 Bergen, Norway
| | - Jian Wang
- Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, 5021 Bergen, Norway
| | - Ernest Dodoo
- Department of Neurosurgery, Karolinska University Hospital, 171 76 Stockholm, Sweden
| | - Jan Ingeman Heggdal
- Department of Oncology and Medical Physics, Haukeland University Hospital, 5021 Bergen, Norway
| | - Janne Grønli
- Department of Biological and Medical Psychology, University of Bergen, 5021 Bergen, Norway
- Norwegian Competence Center for Sleep Disorders, Haukeland University Hospital, 5021 Bergen, Norway
| | - Linda Sleire
- Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, 5021 Bergen, Norway
| | - Sidsel Bragstad
- Department of Neurosurgery, Haukeland University Hospital, 5021 Bergen, Norway
| | - Jeremy C. Ganz
- Department of Neurosurgery, Haukeland University Hospital, 5021 Bergen, Norway
| | - Martha Chekenya
- Brain Tumor Immunology & Therapy Group, Department of Biomedicine, University of Bergen, 5021 Bergen, Norway
| | - Sverre Mørk
- Department of Neurosurgery, Karolinska University Hospital, 171 76 Stockholm, Sweden
| | - Paal-Henning Pedersen
- Department of Neurosurgery, Haukeland University Hospital, 5021 Bergen, Norway
- Institute of Surgical Sciences, Haukeland University Hospital, 5021 Bergen, Norway
| | - Per Øyvind Enger
- Department of Neurosurgery, Haukeland University Hospital, 5021 Bergen, Norway
- Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, 5021 Bergen, Norway
| |
Collapse
|
11
|
Sleire L, Skeie BS, Netland IA, Heggdal J, Pedersen PH, Enger PØ. Abstract 1590: Sulfasalazine sensitizes glioblastoma cells to radiation treatment. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-1590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Glioblastoma (GBM) is a lethal cancer with a limited response to ionizing radiation. Recent studies suggest that Sulfasalazine (SAS), a drug used to treat inflammatory bowel disease, inhibits the Xc− antiporter system in glioma cells, thereby blocking their uptake of cystein. Since the availability of cystein is a rate limiting step in intracellular antioxidant production, we wanted to investigate whether sulfasalazine sensitizes glioma cells to radiation.
Expression of xCT, the catalytic subunit of system Xc−, was found in 30 patient GBM biopsies. SAS effect on glioma cell growth was investigated using an electric cell substrate impedance sensing (ECIS) instrument. All glioma cell lines showed altered growth curves in response to SAS treatment. To assess the effect of blocking the antiporter, intracellular levels of the antioxidant glutathione were measured. With increasing doses of SAS, glutathione levels decreased in a dose response manner. In addition, cysteine was added to the medium to see if the toxic effects of SAS could be counteracted. Furthermore, accumulation of reactive oxygen species upon SAS treatment was measured. Glioma cells were also treated with escalating doses of SAS, alone or in combination with radiation (8 Gy). The presence of double stranded breaks increased markedly in the irradiated samples and also somewhat with increasing doses with SAS. In addition, cell death, viability and clonogenicity were investigated using live/dead staining, the MTS assay and the clonogenic assay.
All treatment groups exhibited increased rates of cell death compared to untreated controls. A combination of SAS and radiation resulted in higher levels of cell death, than radiation or SAS administered alone. Furthermore we continued with implantation of human GBMs into the brain of Nude rats. These animals were treated with Gamma Knife Radiosurgery alone or in combination with SAS. SAS were administered as a pre-treatment for three days before Radiosurgery. The rats receiving the combination treatment lived significantly longer compared to either treatment alone. Interestingly, the animals only receiving pre-treatment with SAS for three days lived significantly longer compared to the untreated controls, although this was not statistically significant. We are currently preparing a clinical trial for patients with GBM recurrences combining pre-treatment with Sulfasalazine and Gamma Knife Radiosurgery.
Citation Format: Linda Sleire, Bente S. Skeie, Inger A. Netland, Jan Heggdal, Paal-Henning Pedersen, Per Ø. Enger. Sulfasalazine sensitizes glioblastoma cells to radiation treatment. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1590. doi:10.1158/1538-7445.AM2013-1590
Collapse
Affiliation(s)
| | | | | | - Jan Heggdal
- 2Haukeland University Hospital, Bergen, Norway
| | | | | |
Collapse
|
12
|
Jacobsen HK, Sleire L, Wang J, Netland IA, Mutlu E, Førde H, Pedersen PH, Gullberg D, Enger PØ. Establishment of a novel dsRed NOD/Scid mouse strain to investigate the host and tumor cell compartments. Cancer Invest 2013; 31:221-30. [PMID: 23521006 DOI: 10.3109/07357907.2013.780075] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Here we describe a NOD/Scid mouse strain expressing the dsRed transgene. The strain is maintained by inbreeding of homozygous dsRed NOD/Scid siblings, and expresses red fluorescence from various organs. The model allows engraftment of human tumor tissue, and engrafted tumors were separated into stromal and malignant cell compartments. Furthermore, we compared tumor-associated and normal fibroblast for expression of fibroblast-associated markers, and identified a marker panel that was upregulated in the tumor-associated fibroblasts. In conclusion, we propose that this model may be used in a variety of studies of tumor progression and to elucidate the role of the tumor microenvironment.
Collapse
Affiliation(s)
- Hege Karine Jacobsen
- Oncomatrix Research Lab, Department of Biomedicine, University of Bergen, Bergen, Norway
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Santacroce A, Walier M, Régis J, Liščák R, Motti E, Lindquist C, Kemeny A, Kitz K, Lippitz B, Martínez Álvarez R, Pedersen PH, Yomo S, Lupidi F, Dominikus K, Blackburn P, Mindermann T, Bundschuh O, van Eck ATCJ, Fimmers R, Horstmann GA. Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery 2012; 70:32-9; discussion 39. [PMID: 21765282 DOI: 10.1227/neu.0b013e31822d408a] [Citation(s) in RCA: 146] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Radiosurgery is the main alternative to microsurgical resection for benign meningiomas. OBJECTIVE To assess the long-term efficacy and safety of radiosurgery for meningiomas with respect to tumor growth and prevention of associated neurological deterioration. Medium- to long-term outcomes have been widely reported, but no large multicenter series with long-term follow-up have been published. METHODS From 15 participating centers, we performed a retrospective observational analysis of 4565 consecutive patients harboring 5300 benign meningiomas. All were treated with Gamma Knife radiosurgery at least 5 years before assessment for this study. Clinical and imaging data were retrieved from each center and uniformly entered into a database by 1 author (A.S.). RESULTS Median tumor volume was 4.8 cm³, and median dose to tumor margin was 14 Gy. All tumors with imaging follow-up < 24 months were excluded. Detailed results from 3768 meningiomas (71%) were analyzed. Median imaging follow-up was 63 months. The volume of treated tumors decreased in 2187 lesions (58%), remained unchanged in 1300 lesions (34.5%), and increased in 281 lesions (7.5%), giving a control rate of 92.5%. Only 84 (2.2%) enlarging tumors required further treatment. Five- and 10-year progression-free survival rates were 95.2% and 88.6%, respectively. Tumor control was higher for imaging defined tumors vs grade I meningiomas (P < .001), for female vs male patients (P < .001), for sporadic vs multiple meningiomas (P < .001), and for skull base vs convexity tumors (P < .001). Permanent morbidity rate was 6.6% at the last follow-up. CONCLUSION Radiosurgery is a safe and effective method for treating benign meningiomas even in the medium to long term.
Collapse
Affiliation(s)
- Antonio Santacroce
- Department of Neurosurgery, Heinrich Heine University, Düsseldorf, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Sleire L, Wang J, Heggdal J, Pedersen PH, Enger PØ. Abstract 1456: Sulfasalazine sensitizes glioblastoma cells to radiation treatment. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-1456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Glioblastoma (GBM) is a lethal cancer with a limited response to ionizing radiation. Recent studies suggest that Sulfasalazine (SAS), a drug used to treat inflammatory bowel disease, inhibits the Xc- antiporter system in glioma cells, thereby blocking their uptake of cystein. Since the availability of cystein is a rate limiting step in intracellular antioxidant production, we wanted to investigate whether sulfasalazine sensitizes glioma cells to radiation. Expression of xCT, the catalytic subunit of system Xc-, was found in 30 patient GBM biopsies. SAS effect on glioma cell growth was investigated using an electric cell substrate impedance sensing (ECIS) instrument. All glioma cell lines showed altered growth curves in response to SAS treatment. To assess the effect of blocking the antiporter, intracellular levels of the antioxidant glutathione were measured. With increasing doses of SAS, glutathione levels decreased in a dose response manner. In addition, cysteine was added to the medium to see if the cells could survive high doses of SAS. U251 glioma cells were treated with escalating doses of SAS, alone or in combination with radiation (8 Gy). Nuclear integrity was evaluated to estimate cell death following treatment, as well as the presence of double stranded breaks. In addition, cell death and viability were investigated using live/dead staining and the MTS assay. All treatment groups exhibited increased rates of cell death compared to untreated controls. A combination of SAS and radiation resulted in higher levels of cell death, than radiation or SAS administered alone. In order to assess whether this can be exploited therapeutically, we are preparing to treat nude rats harbouring glioblastoma biopsy xenografts with SAS, alone or in combination with gamma knife radiation.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1456. doi:1538-7445.AM2012-1456
Collapse
Affiliation(s)
| | | | - Jan Heggdal
- 2Haukeland University Hospital, Bergen, Norway
| | | | | |
Collapse
|
15
|
Skeie BS, Enger PØ, Brøgger J, Ganz JC, Thorsen F, Heggdal JI, Pedersen PH. γ knife surgery versus reoperation for recurrent glioblastoma multiforme. World Neurosurg 2012; 78:658-69. [PMID: 22484078 DOI: 10.1016/j.wneu.2012.03.024] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2011] [Revised: 02/23/2012] [Accepted: 03/29/2012] [Indexed: 12/26/2022]
Abstract
BACKGROUND The optimal management of patients with recurrent glioblastoma multiforme (GBM) is a subject of controversy. These patients may be candidates for both reoperation and/or gamma knife surgery (GKS). Few studies have addressed the role of GKS for relapsing gliomas, and the results have not been compared with reoperation. To validate the efficacy and safety of GKS, we compared the survival and complication rates of GKS and reoperation for recurrent GBMs. METHODS This study retrospectively reviewed 77 consecutive patients with histopathologically confirmed GBMs retreated for recurrent GBM between 1996 and 2007. Thirty-two patients underwent GKS, 26 reoperation and 19 both procedures. RESULTS The median time from the second intervention to tumor progression was longer after GKS than after resection, P = 0.009. Median survival after retreatment was 12 months for the 51 patients receiving GKS compared with 6 months for reoperation only (P = 0.001, hazard ratio [HR] 2.4), and 19 months versus 16 months from the time of primary diagnosis (P = 0.021, HR 1.8). A multivariate analysis adjusted for possible confounding factors (tumor volume, recursive partitioning analysis class, neurological deficits, time to recurrence, adjuvant therapy, and tumor location) showed significantly longer survival for patients treated with GKS, both from retreatment (P = 0.013, HR 4.1) and from primary diagnosis (P = 0.002, HR 5.8). The adjusted results were still significant after separate analysis according to tumor volume <5 mL, 5 to 20 mL, and >20 mL. The complications rate was 9.8% after GKS and 25.2% after reoperation. CONCLUSIONS GKS may be an alternative to open surgery for small GBMs at the time of recurrences, with a significantly lower complication rate and a possible survival benefit compared with reoperation.
Collapse
Affiliation(s)
- Bente Sandvei Skeie
- Department of Surgical Sciences, Haukeland University Hospital, Bergen, Norway.
| | | | | | | | | | | | | |
Collapse
|
16
|
Skeie BS, Skeie GO, Enger PØ, Ganz JC, Heggdal JI, Ystevik B, Hatteland S, Parr E, Pedersen PH. Gamma Knife Surgery in Brain Melanomas: Absence of Extracranial Metastases and Tumor Volume Strongest Indicators of Prolonged Survival. World Neurosurg 2011; 75:684-91; discussion 598-603. [DOI: 10.1016/j.wneu.2010.12.054] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2010] [Revised: 12/03/2010] [Accepted: 12/17/2010] [Indexed: 10/18/2022]
|
17
|
Sleire L, Wang J, Heggdal J, Pedersen PH, Enger PØ. Abstract 2499: Sulfasalazine sensitizes glioblastoma cells to radiation treatment. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-2499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Glioblastomas (GBMs) are lethal cancers with a limited response to ionizing radiation. Recent studies suggest that Sulfasalazine (SAS), a drug used to treat inflammatory bowel disease, inhibits the xCT antiporter system in glioma cells, thereby blocking their uptake of cystein. Since the availability of cystein is a rate limiting step in intracellular antioxidant production, we wanted to investigate whether sulfasalazine sensitizes glioma cells to radiation.
SAS effect on glioma cell growth was investigated using an electric cell substrate impedance sensing (ECIS) instrument. All cell lines showed altered growth curves in response to SAS treatment. To assess the effect of blocking the xCT antiporter, intracellular levels of the antioxidant glutathione were measured. With increasing doses of SAS, glutathione levels decreased in a dose response manner. Further, U251 glioma cells were treated with escalating doses of SAS, alone or in combination with radiation (8 Gy). Nuclear integrity was evaluated to estimate cell death following treatment. In addition, cell death and viability were investigated using live/dead staining and MTS assay respectively.
All treatment groups exhibited increased rates of cell death compared to untreated controls. However, a combination of SAS and radiation resulted in higher levels of cell death, than radiation or SAS administered alone. In order to assess whether this can be exploited therapeutically, we are currently preparing to treat nude rats harbouring gliblastoma biopsy xenografts with SAS, alone or in combination with radiation.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2499. doi:10.1158/1538-7445.AM2011-2499
Collapse
Affiliation(s)
| | | | - Jan Heggdal
- 2Haukeland University Hospital, Bergen, Norway
| | | | | |
Collapse
|
18
|
Jacobsen HK, Sleire L, Wang J, Svendsen A, Pedersen PH, Gullberg D, Enger PØ. Abstract 4320: Separate analysis of the cancer and stroma cell populations from orthotopically implanted cancer cell lines in fluorescent mice. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-4320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The tumour microenvironment is increasingly recognised as important in most aspects of tumourigenesis, from tumor formation, growth and invasion, to metastasis and priming of distant metastatic sites. It has been estimated that around 50% of a solid tumor mass may be of stromal origin, including cells of the immune system, endothelial cells and fibroblasts, with the latter being the most abundant. The fibroblasts recruited to a tumor are commonly known as cancer associated fibroblasts (CAFs), and are characterized by their heterogeneity of marker expression and origin, making them a challenge to study.
Therefore, we have developed a new strain of mice for the analysis of the tumour microenvironment in xenograft models. The strain was created by crossbreeding dsRed positive mice with severe combined immunodeficient (SCID) mice, and backcrossing on a SCID background until we obtained a homozygous dsRed-SCID inbred strain. As the tumor cells implanted are non-fluorescent, whereas the stromal contributions to the growing tumors are dsRed positive, the two compartments were successfully separated by Fluorescence-activated cell sorting (FACS) after mechanical and enzymatic dissociation.
The dsRed phenotype is visibly red with the naked eye, and fluoresces under a 488 nm dark reader lamp light. The organs have been confirmed dsRed positive by imaging and further confirmed and quantified by RT-PCR. The SCID phenotype was confirmed by immune phenotyping, using markers for B, T, Tc, Th and NK cells. Furthermore, the mice were confirmed immune deficient when they were orthotopicaly grafted with breast (4T1) and lung (A549) cancer cell lines.
Fibroblast enriched populations were isolated from primary A549 tumours, 4T1 tumours and 4T1 tumour metastasis to the lungs, by subsorting the dsRed positive stromal compartment, excluding cells of the immune system and endothelial cells. Preliminary data clearly show distinct tumor and stroma populations in primary breast and lung cancer, as well as in lung metastasis from breast cancer xenografts. Furthermore, when investigating the breast cancers dissociated at different time points from implantation, it is clear that the percentage of stromal cells in the overall tumour mass decreases as the tumour grows. The fibroblasts were further analyzed for marker expression, cell cycle phase distribution and in vitro growth properties. We conclude that this model provides a valuable tool for investigating the stromal compartment of xenograft tumours.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4320. doi:10.1158/1538-7445.AM2011-4320
Collapse
Affiliation(s)
| | | | - Jian Wang
- 1University of Bergen, Bergen, Norway
| | | | | | | | | |
Collapse
|
19
|
Sleire L, Wang J, Heggdal J, Pedersen PH, Enger PØ. Abstract LB-169: Sulfasalazine sensitizes glioblastoma cells to radiation treatment. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-lb-169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Glioblastomas (GBMs) are lethal cancers with a limited response to ionizing radiation. Recent studies suggest that Sulfasalazine (SAS), a drug used to treat inflammatory bowel disease, inhibits the xCT antiporter system in glioma cells, thereby blocking their uptake of cystine. Since the availability of cystine is a rate limiting step in intracellular antioxidant production, we wanted to investigate whether sulfasalazine sensitizes glioma cells to radiation. SAS effect on glioma cell growth was investigated using a electric cell substrate impedance sensing (ECIS) instrument. All cell lines showed altered growth curves in response to SAS treatment. Further, U251 glioma cells were treated with escalating doses of SAS, alone or in combination with radiation (8 Gy). Immunocytochemistry for the apoptotic marker Annexin V as well as DAPI staining to assess nuclear integrity were conducted to estimate cell death following treatment.
All treatment groups exhibited increased rates of cell death compared to untreated controls. However, a combination of SAS and radiation resulted in higher levels of cell death, than radiation or SAS administered alone. In order to assess whether this can be exploited therapeutically, we are currently preparing to treat nude rats harbouring gliblastoma biopsy xenografts with SAS, alone or in combination with radiation.
Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-169.
Collapse
Affiliation(s)
| | - Jian Wang
- 1University of Bergen, Bergen, Norway
| | - Jan Heggdal
- 2Haukeland University Hospital, Bergen, Norway
| | | | | |
Collapse
|
20
|
Myrseth E, Møller P, Pedersen PH, Lund-Johansen M. Vestibular schwannoma: surgery or gamma knife radiosurgery? A prospective, nonrandomized study. Neurosurgery 2009; 64:654-61; discussion 661-3. [PMID: 19197222 DOI: 10.1227/01.neu.0000340684.60443.55] [Citation(s) in RCA: 172] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
OBJECTIVE To conduct a prospective, open, nonrandomized study of treatment-associated morbidity in patients undergoing microsurgery or gamma knife radiosurgery (GKRS) for vestibular schwannomas. METHODS Ninety-one patients with vestibular schwannomas with a maximum tumor diameter of 25 mm in the cerebellopontine angle were treated according to a prospective protocol either by GKRS (63 patients) or open microsurgery (28 patients) using the suboccipital approach. Primary end points included hearing function, according to the Gardner-Robertson scale, and facial nerve function, according to the House-Brackmann scale at 2 years. Clinical data included a balance platform test, score for tinnitus and vertigo using a visual analog scale, and working ability. Patients responded to the quality-of-life questionnaires Short-Form 36 and Glasgow Benefit Inventory. RESULTS Three elderly GKRS patients withdrew; all remaining patients were followed for 2 years. Both primary end points were highly significant in favor of GKRS (P < 0.001). Evidence of reduced facial nerve function (House-Brackmann grade 2 or poorer) at 2 years was found in 13 of 28 open microsurgery patients and 1 of 60 GKRS patients. Thirteen of 28 patients who underwent surgery had serviceable hearing (Gardner-Robertson grade A or B) preoperatively, but none had serviceable hearing postoperatively. Twenty-five of 60 GKRS patients had serviceable hearing before treatment, and 17 (68%) of them had serviceable hearing 2 years after treatment. The tinnitus and vertigo visual analog scale score, as well as balance platform tests, did not change significantly after treatment, and working status did not differ between the groups at 2 years. Quality of life was significantly better in the GKRS group at 2 years, based on the Glasgow Benefit Inventory questionnaire. One GKRS patient required operative treatment within the 2-year study period. CONCLUSION This is the second prospective study to demonstrate better facial nerve and hearing outcomes from GKRS than from open surgery for small- and medium-sized vestibular schwannomas.
Collapse
Affiliation(s)
- Erling Myrseth
- Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway.
| | | | | | | |
Collapse
|
21
|
Christophersen IS, Jordal R, Osther K, Lindenberg J, Pedersen PH, Berg K. Interferon therapy in neoplastic disease. A preliminary report. Acta Med Scand 2009; 204:471-6. [PMID: 282780 DOI: 10.1111/j.0954-6820.1978.tb08475.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The treatment of 10 patients having neoplastic disease with exogenous i.m. interferon therapy is described. The interferon given is partially purified interferon produced from human leukocytes. Sendai virus is used as interferon inductor. The patients reported in this paper have been on treatment for periods of 2-28 months. Apart from initial periods of fever, no side-effects have been recorded. Patients suffering from bladder papillomas have shown partial regression after a few months of therapy. The other cases treated are too few to warrant any conclusions, but the therapy does seem to have been beneficial.
Collapse
|
22
|
Vik-Mo EO, Øksnes M, Pedersen PH, Wentzel-Larsen T, Rødahl E, Thorsen F, Schreiner T, Aanderud S, Lund-Johansen M. Gamma knife stereotactic radiosurgery of Nelson syndrome. Eur J Endocrinol 2009; 160:143-8. [PMID: 18996962 DOI: 10.1530/eje-08-0687] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Gamma knife radiosurgery (GKR) can be used as primary or adjuvant therapy for the treatment of an ACTH-producing pituitary tumor after bilateral adrenalectomy, called Nelson syndrome (NS). We have examined the effect of GKR on tumor growth and ACTH-hypersecretion, and characterized the adverse events of this treatment in patients with NS. DESIGN Cross-sectional follow-up study. First, retrospective data pre- and post-GKR were collected. Patients then underwent a predefined survey including radiological, endocrinological, ophthalmological, and neurosurgical evaluation. SUBJECTS Ten patients treated with GKR for NS after previous bilateral adrenalectomy. The mean follow-up was 7 years. No patient was lost to follow-up. RESULTS Tumor growth was stopped in all patients. The ACTH levels declined in eight patients, and normalized in one patient. There was a significant drop in ACTH levels, with a half-time of 2.8 years. No patient developed visual field defects or any other cranial nerve dysfunction as a result of treatment. Four patients started hormone substitution therapy during the follow-up period. The substitution therapy of three pituitary axes present at GKR treatment could be stopped during the same period. One patient developed a glioblastoma in the left parieto-occipital region 14 years after GKR, far from the field of treatment. As the radiation level was below 1Gy to this area, it is unlikely that the GKR treatment itself induced the malignant tumor. CONCLUSION In patients with NS, GKR is an effective adjuvant treatment, carrying relatively few adverse effects. Although the risk of developing a secondary neoplasia after GKR is present, it is probably extremely low.
Collapse
Affiliation(s)
- Einar Osland Vik-Mo
- Department of Neurosurgery, Haukeland University Hospital, 5053 Bergen, Norway.
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Vik-Mo EO, Oksnes M, Pedersen PH, Wentzel-Larsen T, Rødahl E, Thorsen F, Schreiner T, Aanderud S, Lund-Johansen M. Gamma knife stereotactic radiosurgery for acromegaly. Eur J Endocrinol 2007; 157:255-63. [PMID: 17766706 DOI: 10.1530/eje-07-0189] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Gamma knife radiosurgery (GKR) is an adjuvant treatment for acromegaly if surgery fails to normalize GH hypersecretion. OBJECTIVE To examine the effect of GKR on tumor growth and hypersecretion, and to characterize the adverse effect of this treatment. DESIGN Cross-sectional follow-up study. First, retrospective data pre- and post-GKR were collected. PATIENTS then underwent a predefined survey including radiological, endocrinological, ophthalmological, and neurosurgical evaluation. SETTING Norwegian National Center for gamma knife treatment. PATIENTS Sixty-one patients treated with GKR for acromegaly. Out of 55, 53 living patients underwent a detailed survey. The mean follow-up was 5.5 years. No patient was lost to follow-up. RESULTS Tumor growth was stopped in all patients. At 3, 5, and 10 years after GKR, 45, 58, and 86% of patients had normal IGF-I levels. Consecutive hormone value analysis showed that patients receiving GH-suppressive medication had a more rapid decline in hypersecretion than those who did not receive such medication. Evaluated by survey baseline values alone, non-elevated IGF-I and GH levels below 5 mIU/l were found in 38%. GH-suppressive medication was terminated in 16 out of 40 patients following GKR. Nine out of 53 surveyed patients (17%) had normal IGF-I and GH nadir below 2.6 mIU/l at glucose tolerance tests, while not on hormone-suppressive medication. Two patients developed minor visual field defects. Eight patients started hormone substitution therapy during the follow-up period. CONCLUSION GKR is an effective adjuvant treatment for residual acromegaly, carrying few side effects.
Collapse
|
24
|
Thorsen F, Enger PØ, Wang J, Bjerkvig R, Pedersen PH. Human glioblastoma biopsy spheroids xenografted into the nude rat brain show growth inhibition after stereotactic radiosurgery. J Neurooncol 2006; 82:1-10. [PMID: 16955221 DOI: 10.1007/s11060-006-9240-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2006] [Accepted: 08/08/2006] [Indexed: 10/24/2022]
Abstract
BACKGROUND The Gamma Knife is currently used to boost treatment of malignant gliomas. However, few experimental studies have focused on its radiobiological effects. In this work, the growth and invasiveness of human glioblastoma spheroids xenografted into nude rat brains were assessed after radiosurgery. Temporary in vitro as well as long-term in vivo radiation effects were studied. METHODS Glioblastoma biopsy spheroids were irradiated with 12 or 24 Gy. Short-term in vitro spheroid viability and tumour cell migration was determined by microscopic techniques. Pre-irradiated glioblastoma spheroids were implanted into brains of immunosuppressed rats. Long-term tumour development was assessed by magnetic resonance (MR) imaging, and animal survival was recorded. An immunohistochemical analysis was performed on the sectioned rat brains. RESULTS Both un-irradiated and irradiated spheroids remained viable during 2 months in culture, but a dose-dependent inhibition of tumour growth and migration was seen. MR imaging 4 weeks after implantation also showed a dose-dependent inhibition in tumour development. Median animal survival times were 25.5 days (control group), 43 days (12 Gy group) and 96 days (24 Gy group). The study of in vivo long-term radiation effects on the remaining viable tumour population showed no difference in Ki-67 labelling index and microvascular density before and after radiosurgery. CONCLUSIONS A dose-dependent inhibition of tumour growth and invasion, as well as a dose-dependent increase in animal survival was observed. The model system described is well suited for assessing the radiobiological effects of Gamma Knife radiosurgery. The results indicate that radiosurgery of malignant gliomas might be effective in controlling tumour progression in selected glioblastoma patients.
Collapse
Affiliation(s)
- Frits Thorsen
- Department of Oncology and Medical Physics, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.
| | | | | | | | | |
Collapse
|
25
|
Myrseth E, Møller P, Pedersen PH, Vassbotn FS, Wentzel-Larsen T, Lund-Johansen M. Vestibular schwannomas: clinical results and quality of life after microsurgery or gamma knife radiosurgery. Neurosurgery 2006; 56:927-35; discussion 927-35. [PMID: 15854240 DOI: 10.1055/s-2005-916493] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2004] [Accepted: 11/10/2004] [Indexed: 10/19/2022] Open
Abstract
OBJECTIVE The aim of the present study was to evaluate the overall treatment efficacy (tumor control, facial nerve function, complications) and quality of life for patients treated primarily for unilateral vestibular schwannomas of 30 mm or less, either by microsurgery or by gamma knife (GK) radiosurgery. The results for the two treatment groups are compared with each other, with main emphasis on the long-term quality of life. METHODS This is a retrospective study of 189 consecutive patients, 86 treated by microsurgery and 103 by gamma knife. The mean observation time was 5.9 years. All patients had a magnetic resonance imaging scan and clinical evaluation performed toward the end of the study. To evaluate the quality of life, we used two standardized questionnaires, the Glasgow Benefit Inventory and Short-Form 36. The questionnaires were sent to the 168 living patients. The reply rate was 83.3%. RESULTS A total of 79.8% of the patients in the microsurgery group and 94.8% of the GK patients had a good facial nerve function (House-Brackmann Grade 1-2). Hearing was usually lost after microsurgery, whereas the GK patients had preserved hearing, which often became reduced over the years after the treatment. The treatment efficacy, defined as no need for additional treatment, was similar for the two treatment modalities. Quality of life was reduced compared with normative data, being most reduced in the microsurgery group. Some of the quality of life questions showed an association with facial nerve function and sex. CONCLUSION Posttreatment facial nerve function, hearing, complication rates, and quality of life were all significantly in favor of GK radiosurgery.
Collapse
Affiliation(s)
- Erling Myrseth
- Department of Surgical Sciences, Section for Neurosurgery, Haukeland University Hospital, Bergen, Norway.
| | | | | | | | | | | |
Collapse
|
26
|
Myrseth E, Moller P, Pedersen PH, Vassbotn FS, Wentzel-Larsen T, Lund-Johansen M. Vestibular schwannomas: Clinical results and quality of life after microsurgery or gamma knife radiosurgery. Neurosurgery 2005;56:927-935. Skull Base 2005. [DOI: 10.1055/s-2005-925545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
27
|
Myrseth E, Moller P, Pedersen PH, Vassbotn FS, Wentzel-Larsen T, Lund-Johansen M. Vestibular schwannomas: Clinical results and quality of life after microsurgery or gamma knife radiosurgery. Neurosurgery 2005;56:927-935. Skull Base 2005. [DOI: 10.1055/s-2006-932412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Hirth A, Pedersen PH, Wester K, Mörk S, Helgestad J. Cerebral atypical teratoid/rhabdoid tumor of infancy: long-term survival after multimodal treatment, also including triple intrathecal chemotherapy and gamma knife radiosurgery--case report. Pediatr Hematol Oncol 2003; 20:327-32. [PMID: 12746165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
Cerebral atypical teratoid/rhabdoid tumors (AT/RT) of infancy are highly malignant and have a poor prognosis. The authors report on one case with long-term survival. The patient was a 1 year-old boy presenting with a large AT/RT in the right temporal lobe. He was treated with complete surgery, followed by multiagent chemotherapy. Later he had a second resection and intrathecal chemotherapy and Gamma knife radiosurgery was added to the treatment. Except for a well-controlled temporal epilepsy, the boy is doing well after 6 years follow-up. AT/RT should be treated in a multimodal way. Intrathecal chemotherapy and Gamma knife radiosurgery of single recurrent or residual tumors might increase survival.
Collapse
Affiliation(s)
- Asle Hirth
- Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.
| | | | | | | | | |
Collapse
|
29
|
Hirth A, Pedersen PH, Baardsen R, Larsen JL, Krossnes BK, Helgestad J. Gamma-knife radiosurgery in pediatric cerebral and skull base tumors. Med Pediatr Oncol 2003; 40:99-103. [PMID: 12461793 DOI: 10.1002/mpo.10218] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND This retrospective study of 12 children with cerebral or skull base tumors was undertaken to evaluate morbidity and outcome after gamma-knife surgery. PROCEDURE Twelve consecutive children treated with stereotactic radiosurgery in a curative intent were reviewed. There were five girls and seven boys. The mean age at diagnosis was 5.8 years and at radiosurgical treatment 8.4 years. There were four pilocytic astrocytomas, two craniopharyngeomas, two pineoblastomas, two ependymomas, and two other tumors of high malignancy. We used a 201-source Co60 Leksell gamma knife and all children were treated in general anesthesia. RESULTS The mean tumor volume was 3.7 cm(3) and the mean tumor margin dose was 13.8 Gy. Seven patients remained stable after gamma-knife treatment with a mean follow- up of 78.6 months. One patient died during follow-up. The remaining four patients had progressive disease, two within and two outside the irradiated field, and have received further treatment. They are still alive with and without disease with a mean follow-up of 96.8 months. CONCLUSION Gamma-knife surgery is an effective treatment in some non-resectable cerebral and skull base pediatric tumors. In most cases, it is used in combination with other therapeutic modalities. It is safe and well tolerated.
Collapse
Affiliation(s)
- Asle Hirth
- Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.
| | | | | | | | | | | |
Collapse
|
30
|
Møller P, Myrseth E, Pedersen PH, Kråkenes J, Larsen JL, Moen G. [Treatment of acoustic neuroma]. Tidsskr Nor Laegeforen 2002; 122:1467-70. [PMID: 12185735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023] Open
Abstract
BACKGROUND Acoustic neuroma is the most common tumour in the cerebello-pontine angle. MATERIAL AND METHODS We present the results after surgery in 99 cases, and the natural course of the disease in 82 patients followed for up to 20 years (mean 3 years). RESULTS During the observation period, 43% of the tumours increased in size. 36% of patients suffered increasing hearing loss. Total removal was accomplished in 92 cases. In 12 cases hearing preservation was attempted; successfully in five cases. 72 patients had normal or near normal postoperative facial nerve function, whereas 19 patients got a facial nerve paralysis. Two patients died, one because of haemorrhagic infarction and cerebellar swelling, and one because of ventricular fibrillation. Five patients had to be reoperated for CSF leakage. INTERPRETATION Acoustic neuroma treatment is still a challenge. We favour a team approach to treat this condition.
Collapse
Affiliation(s)
- Per Møller
- Øre-nese-halsavdelingen, Haukeland Sykehus 5021 Bergen.
| | | | | | | | | | | |
Collapse
|
31
|
Pedersen PH, Baardsen R, Larsen JL, Thorsen F, Wester K. [Stereotactic radiosurgery of cerebral arteriovenous malformations]. Tidsskr Nor Laegeforen 2002; 122:1277-80. [PMID: 12098921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023] Open
Abstract
BACKGROUND Different treatment modalities are being used for cerebral arteriovenous malformations. MATERIAL AND METHODS We have evaluated the results of stereotactic radiosurgery on 85 patients (48 females) with median age 34.5 years (range 4-70 years) treated at Haukeland University Hospital in Norway in 1989-96. Median follow-up time was 7 years 3 months (range 51-144 months). Data were obtained retrospectively from patient files. RESULTS Haemorrhage was the initial symptom in 72 patients. The majority of lesions were located deep within the brain parenchyma or near critical structures. The minimum dose to the periphery of the malformation was 15 to 33.3 Gy in 30-70% isodose line according to the volume and location of the malformation. Complete obliteration was obtained in 65 of 85 malformations (77%) and in two of five patients who were retreated. 85% of the malformations smaller than 4 cm3; 50% of those larger than 4 cm3 were obliterated after the treatment. The majority of the malformations were obliterated between two and three years after radiation. Radiation-related side effects were observed in six patients. Five patients experienced new bleeding during follow-up. INTERPRETATION Small and medium-sized arteriovenous malformations are successfully treated with stereotactic radiosurgery with an acceptable rate of radiation-related side effects and latency bleeding.
Collapse
|
32
|
Møller P, Myrseth E, Pedersen PH, Larsen JL, Krakenes J, Moen G. Acoustic neuroma--treatment modalities. Surgery, gamma-knife or observation? Acta Otolaryngol Suppl 2001; 543:34-7. [PMID: 10908970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
We present our results of 211 patients with acoustic neuroma over a period of 10 years, 1988-97. We operated on 100 and 111 had Gamma-knife (GK) treatment (69 were available to follow-up). The results are excellent for surgery on small and intracanalicular tumours. In tumours of the same size, surgery and GK treatment give comparable, but somewhat different, results. In the GK group of 54 primary treated patients, 3 patients had to be operated on and another 4 developed hydrocephalus. A group of 35 acoustic tumours was observed for more than 3 years. Nineteen did grow (54%). Hearing was unchanged in 23%. We performed surgery in 11 patients and gave 2 patients GK treatment because of tumour growth of > 2 mm in diameter a year. We conclude that either treatment is effective for small and medium-sized acoustic neuromas. Hearing preservation was best in the GK-treated group (80%), compared to only 12.5% in the group operated via the suboccipital route. Larger tumours and most medium-sized tumours should be operated, as should smaller tumours with persistent symptoms of vertigo and pain. Medical contraindications to surgery or reluctance to undergo surgery make GK treatment a good alternative. Treatment of residual tumours with the GK could also be a solution to a difficult problem.
Collapse
Affiliation(s)
- P Møller
- Department of Otolaryngology, Head and Neck Surgery, Haukeland Hospital, University of Bergen, Norway
| | | | | | | | | | | |
Collapse
|
33
|
Andersen M, Bjerre P, Schrøder HD, Edal A, Høilund-Carlsen PF, Pedersen PH, Hagen C. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol (Oxf) 2001; 54:23-30. [PMID: 11167922 DOI: 10.1046/j.1365-2265.2001.01172.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The secretory capacity, in vivo, of clinically non-functioning pituitary adenomas may possibly predict tumour volume reduction during intensive medical therapy. Ten patients (mean (range) 53 years (26-73)) with clinically non-functioning macroadenomas, > or = 10 mm were studied. The secretory capacity of the adenomas was examined using basal, NaCl and TRH-stimulated LH, FSH and alpha-subunit levels. The effect on tumour volume of 6 months' therapy with the combination of a somatostatin analogue, octreotide 200 microg x 3/day and a dopamine-D2-agonist, cabergoline 0.5 mg x 1/day was studied. The basal LH, FSH and alpha-subunit levels were determined before and during 6 months' therapy with octreotide and cabergoline, and MR scans were used to evaluate tumour volume before and during this period of therapy. Octopus-perimetry was used to examine the visual fields. A reduction in tumour volume (mean +/- SEM (range); 30% +/- 4% (18-46%)) during 6 months of combination therapy with octreotide and cabergoline was recorded only in patients with in vivo secretory potential. Tumour volume was not reduced in four patients: in three of these patients it remained unchanged while in one patient it was observed to have increased (by 14%). Of the six patients with pretherapy secretory capacity, one displayed a very high basal level of alpha-subunit (74 microg/l) despite unmeasurable levels of LH and TSH, and an FSH-level of 1 IU/l. The other five patients presented paradoxical LH, FSH and/or alpha-subunit responses to TRH. A reduction in basal levels of LH, FSH and/or alpha-subunit was observed in all six patients, and the maximum reduction of at least one of the hormonal levels was 66% +/- 7% (50-98%). The basal levels of LH, FSH and alpha-subunit in the 10 patients were (mean +/- SEM (range)), 3.0 IU/l +/- 1.0 (0.0-7.4), 12.7 IU/l +/- 5.0 (0.0-39.0) and 9.0 IU/l +/- 7.0 (0.2-74.0). During six months of therapy with octreotide and cabergoline, the basal levels of LH, FSH and alpha-subunit were reduced by > or = 50% in seven patients - including the six patients with in vivo secretion prior to therapy. No new visual field defects were detected during therapy and no deterioration of existing visual field defects was recorded. The medical therapy was well tolerated. The in vivo basal and TRH-stimulated secretory capacity of LH, FSH and alpha-subunit predicted tumour reduction following intensive medical therapy in all of our patients with non-functioning pituitary adenomas.
Collapse
Affiliation(s)
- M Andersen
- Department of Endocrinology, Odense University Hospital, 5000 Odense C, Denmark.
| | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
PURPOSE To assess the validity of low-field MR in staging cervical cancer compared to clinical staging. MATERIAL AND METHODS A total of 95 women entered the study over a 3-year period. MR examinations with a 0.1 T resistive magnet using a body coil and clinical staging according to the FIGO recommendations (1988) were performed within 2 weeks from clinical diagnosis. T1- and T2-weighted sequences were obtained in transversal and sagittal acquisitions, and an additional T1 before and after contrast (randomisation to 0.1 or 0.3 mmol/kg b.w. gadodiamide). Treatment decisions on surgery or radiation therapy were made solely on the clinical staging. RESULTS Sixty-one patients were found to be eligible for surgery. In 5 women, the pathological results revealed a more advanced stage of the disease than assessed by clinical staging. MR correctly staged 4 of the 5 but otherwise tended to overstate the disease. Contrast enhancement significantly reduced this trend (p<0.05) regardless of the contrast medium dose used. Divided into two groups, an operable (less than stage 2b) and an inoperable group (more than stage 2a), the clinical staging correctly classified 57 patients (accuracy 92%) compared to 52 patients with MR using contrast enhancement (accuracy 84%). The specificity was no higher than 31%, whereas the reproducibility of the MR assessment was fairly good with kappa values around 0.65 for both intra- and inter-observer variations. CONCLUSION In the present set-up, clinical assessment was superior to low-field MR in staging cervical cancer. When using contrast enhancement, the staging accuracies of low-field MR were comparable to the ones reported for techniques with higher tesla values, whereas the specificity and reproducibility errors were lower. The method, therefore, needs to be optimised.
Collapse
Affiliation(s)
- M A Hansen
- Department of Diagnostic Radiology, Copenhagen University Hospital at Herlev, Denmark
| | | | | | | | | |
Collapse
|
35
|
Jensen HH, Hussain SF, Pedersen PH, Andreasson B. [Atypical endometrial hyperplasia. Prognosis and course]. Ugeskr Laeger 2000; 162:666-9. [PMID: 10707601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
The treatment of patients with the diagnosis atypical endometrial hyperplasia has been disputed during the last decades. The aim of the study was to evaluate the treatment of these patients and analyse the progression rate to invasive carcinoma of the endometrium. Fifty-seven patients with atypical hyperplasia were examined and treated from 1976 through 1991. The medical records were examined retrospectively and the pathology slides were revised by one pathologist in accordance with the 1975 WHO recommendations. Thirty-one (54%) patients were on oestrogen treatment as monotherapy at the time of diagnosis. Forty-two patients had a hysterectomy performed within five months, and five patients had a hysterectomy performed 10 to 61 months after diagnosis. A total of 18 out of 57 patients (31.6%) had or developed endometrial carcinoma all with myometrial invasion: 14 stage I with < or = 50% myometrial invasion, three stage I with > 50% myometrial invasion, and one stage IV. There was no significant difference in age, body mass index, parity or hormone replacement treatment between the group with endometrial carcinoma and the group without endometrial carcinoma. We conclude that unopposed oestrogen treatment and nulliparity are the main risk factors for atypical hyperplasia and that hysterectomy is the appropriate treatment for patients with atypical hyperplasia of the endometrium.
Collapse
Affiliation(s)
- H H Jensen
- Gynaekologisk afdeling og patologisk anatomisk institut, Amtssygehuset i Herlev
| | | | | | | |
Collapse
|
36
|
Rødahl E, Pedersen PH, Bjerkvig R, Haarr L. Infection of rat brain cell aggregates with neurovirulent and nonneurovirulent strains of herpes simplex virus type 1. Exp Cell Res 1999; 248:306-13. [PMID: 10094836 DOI: 10.1006/excr.1998.4348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Rat brain cell aggregates represent a three-dimensional tissue culture system of brain tissue in the form of small, multicellular spheroids. In the present work, we have infected these "minibrains" with neurovirulent, nonneurovirulent, and nonreplicating strains of HSV-1. The neurovirulent strains 17(+) and KOS(M) spread rapidly through the aggregates, while the nonreplicating ICP4 deletion mutant KD6 infected cells only at the periphery of the aggregates. Spread and replication of the nonneurovirulent strains RE6 and tk-7, and to some extent also of R13/1, were restricted. The interaction between different strains of HSV-1 and the rat brain cell aggregates is thus comparable to that seen in the brain, suggesting that the aggregates represent a useful tool for studying HSV-1 infection of brain tissue in vitro.
Collapse
Affiliation(s)
- E Rødahl
- Centre for Research in Virology, University of Bergen, Bergen, N-5020, USA.
| | | | | | | |
Collapse
|
37
|
Terzis AJ, Pedersen PH, Feuerstein BG, Arnold H, Bjerkvig R, Deen DF. Effects of DFMO on glioma cell proliferation, migration and invasion in vitro. J Neurooncol 1998; 36:113-21. [PMID: 9525811 DOI: 10.1023/a:1005811403041] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The polyamine inhibitor DL-alpha-difluoromethylornithine (DFMO) is a specific irreversible inhibitor of ornithine decarboxylase which is a rate-limiting enzyme in the polyamine bio-synthesis pathway. The present study describes the effects of DFMO on glioma cell proliferation, migration and invasion using multicellular spheroids from three glioma cell lines (GaMg, U-251 Mg and U-87 Mg). 10 mM DFMO reduced cell migration in the three cell lines by about 30-50%. 1 mM putrescine, added together with DFMO inhibited the DFMO effect. A stronger effect was observed in the growth assay where 10 mM DFMO reduced the spheroid growth, for all cell lines, by 90%. This effect was also reversed by adding 1 mM of putrescine. In vitro tumor cell invasion experiments indicated after 3 days of confrontation, an extensive invasion also after 10 mM DFMO treatment. The brain aggregate volumes were reduced to about the same extent as in the absence of drug, suggesting essentially no effects of DFMO on the invasive process. It is concluded that the tumor spheroids retained their ability to invade normal brain tissue even after DFMO exposure. However, DFMO inhibited spheroid growth and cell migration which supports the notion that cell growth, migration and invasion are biological properties that are not necessarily related to each other.
Collapse
Affiliation(s)
- A J Terzis
- Department of Neurosurgery, Luebeck, Germany
| | | | | | | | | | | |
Collapse
|
38
|
Poulsen HK, Jacobsen M, Bertelsen K, Andersen JE, Ahrons S, Bock JE, Bostofte E, Engelholm SA, Hølund B, Jakobsen AK, Kiaer H, Nyland MH, Pedersen PH, Christophersen IS. [Patients with early stages of endometrial cancer should be spared adjuvant radiotherapy. Danish Endometrial Cancer Group]. Ugeskr Laeger 1997; 159:3403-7. [PMID: 9199028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
In an attempt to create uniform nationwide guidelines for the management of all stages of endometrial carcinoma, and to limit the use of adjuvant radiation therapy in stage I disease to high-risk patients only, a protocol was developed by the Danish Endometrial Cancer group (DEMCA). From September 1986 through August 1988, 1214 women in Denmark with newly diagnosed carcinoma of the endometrium have been treated according to this protocol. This figure represents all endometrial carcinomas diagnosed in Denmark during this two-year period. The primary treatment was total abdominal hysterectomy and bilateral salpingo-oophorectomy, no preoperative radiation therapy was delivered. In 1039 cases no macroscopic residual tumour and/or microscopic tumor tissue in the resection margins was found following surgery. Based on surgery and histopathology, these patients were classified as: P-stage I low risk (n = 641), P-stage I high risk (n = 235), P-stage II (n = 105) and P-stage III, Group 1 (n = 58). No postoperative radiation therapy was given to P-I low risk cases. P-I high risk, P-II, and P-III (Group 1) cases received external radiation therapy. Recurrence rate at 68-92 months follow-up was 45/641 (7%) in P-I low risk, 36/235 (15%) in P-I high risk, 30/105 (29%) in P-II, and 27/58 (47%) in P-III (Group 1) cases. Fifteen of 17 vaginal recurrences in P-I low risk cases were salvaged (mean observation time 61 months). In this population-based investigation it has been shown that P-stage low-risk patients are adequately treated by total abdominal hysterectomy and bilateral salpingo-oophorectomy, and that no pre- or postoperative radiation therapy is necessary.
Collapse
Affiliation(s)
- H K Poulsen
- Odense Universitetshospital, Den danske endometriecancergruppe (DEMCA)
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Baardsen R, Larsen JL, Wester K, Pedersen PH. [Cerebral metastases treated with stereotaxic gamma radiation. 6-year experience with the "gamma knife" at the Haukeland hospital]. Tidsskr Nor Laegeforen 1997; 117:1591-5. [PMID: 9198941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
During the last 6 years we have treated 32 patients with 45 metastases to the brain in the Gamma Knife unit. 21 of these were treated exclusively with the Gamma Knife. The remaining 11 patients received radiosurgery for recurrent disease after surgery and whole-brain irradiation (six patients), new metastases after whole-brain irradiation alone (three patients) or for local regrowth after surgery (two patients). The range of tumour volume was 0.1-43.3 cm3 (median 2.4 cm3). Marginal tumour dose was 5-30 Gy (median and mean: 25 Gy) to the 30-70% isodose-volume line according to tumour volume and localization. 19 patients died during the period of follow-up. Only three patients died from their intracranial metastases. Thus, local growth control was achieved in 29 patients. 16 patients died from extracranial manifestations. The average survival time for the patients who died during the observation period was 11 (1-37 months), and the survival time for patients still alive was 10-75 (median 14, average 29) months. Mean observation period for all patients was 17 (1-75) months. Brain metastases are physically and biologically ideal lesions to treat with radiosurgery. Stereotactic radiosurgery applied to radiographically small and distinct metastases is safe, non-invasive and highly effective. The treatment requires only a short stay in hospital, and is much less inconvenient to the patient than open surgery or whole-brain irradiation. Radiosurgery can be used on lesions inaccessible to open neurosurgery or resistant to classical fractionated radiotherapy. Gamma Knife treatment has become our first choice for patients with less than four intracranial metastases with diameters less than 3-3.5 cm.
Collapse
Affiliation(s)
- R Baardsen
- Nevrokirurgisk avdeling, Haukeland Sykehus, Bergen
| | | | | | | |
Collapse
|
40
|
Pedersen PH, Edvardsen K, Garcia-Cabrera I, Mahesparan R, Thorsen J, Mathisen B, Rosenblum ML, Bjerkvig R. Migratory patterns of lac-z transfected human glioma cells in the rat brain. Int J Cancer 1995; 62:767-71. [PMID: 7558428 DOI: 10.1002/ijc.2910620620] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Malignant brain tumors are characterized by extensive tumor-cell infiltration into the normal brain tissue. The present work describes the migratory behavior of human glioma cells transplanted into the adult rat brain with the aim of exploiting the extent of active cell migration and passive cell displacement within the central nervous system. To detect every transplanted tumor cell, a stably bacterial beta-galactosidase (lac-z) transfected human glioma cell line was used. To distinguish between an active cell migration process and passive cell displacement, rat brains were also implanted with inert fluorescent polystyrene microspheres and the distribution of tumor cells and microspheres was studied 1 hr and 3 days after implantation. One hour after implantation the tumor cells were strictly localized at the implantation site. However, 3 days after implantation, both tumor cells and microspheres showed an extensive distribution within the brain. Confirming earlier neuropathological and experimental studies, it is shown that the lac-z-transfected glioma cells had the capacity to move within the Virchow-Robin and subarachnoid spaces. However, since fluorescent microspheres were also found in these areas, this spread of tumor cells may be primarily mediated by the extensive cerebrospinal fluid flow that exists within the brain. Three days after implantation, the glioma cells also showed an active migration over the corpus callosum. In comparison, the fluorescent microspheres showed only limited spread along the callosal body. It is concluded that the bacterial lac-z gene can be stably transfected into human glioma cells and, since every tumor cell can be visualized within the brain, this model provides a tool for studying the mechanisms behind tumor-cell invasion of the brain.
Collapse
Affiliation(s)
- P H Pedersen
- Gade Institute, Department of Pathology, University of Bergen, N-5021 Haukeland Hospital, Norway
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Pedersen PH, Rucklidge GJ, Mørk SJ, Terzis AJ, Engebraaten O, Lund-Johansen M, Backlund EO, Laerum OD, Bjerkvig R. Leptomeningeal tissue: a barrier against brain tumor cell invasion. J Natl Cancer Inst 1994; 86:1593-9. [PMID: 7932823 DOI: 10.1093/jnci/86.21.1593] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND Primary brain tumors are characterized by an extensive infiltrative growth into the surrounding brain tissue. This process is confined to the central nervous system, and tumor cell metastasis to other organs is rare. However, other tumors of non-neural origin may frequently metastasize to the central nervous system. PURPOSE The purpose of the present study was to examine the invasive behavior of different glioma cells into tissues of neural (brain aggregates) as well as non-neural origin (leptomeningeal tissue). Using the same target tissues, the invasive characteristics of two neural metastatic tumors (one malignant melanoma and one small-cell lung carcinoma) were also studied. This direct comparison of the invasive behavior between tumors of neural and non-neural origin provides valuable information regarding the mechanisms of glioma cell dissemination in the central nervous system. METHODS The in vitro invasive behavior of human tumors of the central nervous system into human leptomeningeal tissue as well as into normal rat brain tissue was studied. For this purpose, a co-culture system consisting of tumor biopsy specimens, human leptomeningeal cell aggregates, and brain cell aggregates was established. Three glioblastomas, one oligodendroglioma, one meningioma, one small-cell lung carcinoma, and one malignant melanoma were studied. RESULTS In co-cultures of gliomas and leptomeningeal cell aggregates, a well-defined border between the two tissues was observed. The brain cell aggregates, in contrast, were consistently invaded by the glioma cells. The brain metastases showed a different invasion pattern. The metastatic cells invaded and progressively destroyed leptomeningeal cell aggregates, whereas they did not invade the brain cell aggregates. Upon confrontation of the leptomeningeal tissue with the meningioma, a fusion of the two tissues was observed. Immunostaining of the leptomeningeal tissue showed a strong expression of the basement membrane components fibronectin, collagen type IV, and laminin with no expression of glial fibrillary acidic protein, neuron-specific enolase, or S-100 protein. CONCLUSIONS The present study indicates that there may be important biologic differences between the invasive behavior of gliomas and non-neuroepithelial tumors. Our co-culture experiments suggest that leptomeningeal cells and associated acellular components may constitute a barrier against glioma cell invasion. However, this barrier may not be functional for metastatic tumors to the brain. The presence of glioma cells within the leptomeninges should not necessarily be taken as evidence of aggressive growth or as an indicator of malignancy.
Collapse
Affiliation(s)
- P H Pedersen
- Gade Institute Department of Pathology, University of Bergen, Norway
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Ness GO, Pedersen PH, Bjerkvig R, Laerum OD, Lillehaug JR. Three-dimensional growth of glial cell lines affects growth factor and growth factor receptor mRNA levels. Exp Cell Res 1994; 214:433-6. [PMID: 8082746 DOI: 10.1006/excr.1994.1277] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We have studied, at the mRNA level, the influence of various defined growth conditions on the expression of TGF-alpha, PDGF-BB, EGF-R, PDGF-R alpha, and PDGF-R beta in five different glioma cell lines (D-37MG, D-54MG, D-263MG, GaMG, and U-251MG). RNA isolated from logarithmically growing, confluent monolayer cells or multicellular spheroids was analyzed. Northern blot experiments show that with a few exceptions, specific mRNA steady-state levels were considerably higher in cells grown in a three-dimensional organization relative to cells in the logarithmic growth phase.
Collapse
Affiliation(s)
- G O Ness
- Department of Biochemistry and Molecular Biology, University of Bergen, Norway
| | | | | | | | | |
Collapse
|
43
|
Edvardsen K, Pedersen PH, Bjerkvig R, Hermann GG, Zeuthen J, Laerum OD, Walsh FS, Bock E. Transfection of glioma cells with the neural-cell adhesion molecule NCAM: effect on glioma-cell invasion and growth in vivo. Int J Cancer 1994; 58:116-22. [PMID: 8014007 DOI: 10.1002/ijc.2910580119] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The tumor growth and the invasive capacity of a rat glioma cell line (BT4Cn) were studied after transfection with the human transmembrane 140-kDa isoform of the neural-cell adhesion molecule, NCAM. After s.c. injection, the NCAM-transfected cells showed a slower growth rate than the parent cell line (BT4Cn). Upon intracerebral implantation with BT4Cn cells and different clones of NCAM-transfected cells, all animals developed neurological symptoms within 13-16 days. However, the tumors showed different growth characteristics. The NCAM-transfected BT4Cn cells were localized in the region of the injection site, with a sharply demarcated border between the tumor and brain tissue. In contrast, the parental cell line showed single-cell infiltration and more pronounced destruction of normal brain tissue. Using a 51Cr-release assay, spleen cells from rats transplanted with BT4Cn tumor cells generally showed a lower cytotoxic response than the spleen cells from rats transplanted with the transfected variants of BT4Cn cells, indicating that the transfection procedure in itself mediated an activation of the immune system. The present data suggest that NCAM may influence the malignant behavior of rat glioma cells in vivo.
Collapse
Affiliation(s)
- K Edvardsen
- Research Center for Medical Biotechnology, University of Copenhagen, Panum Institute, Denmark
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Pedersen PH, Klitgaard NA, Hørder M, Blåbjerg O, Grindsted P. [Clinical needs for standardization of HbA1C]. Ugeskr Laeger 1994; 156:3195. [PMID: 8066841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
45
|
Marienhagen K, Pedersen PH, Terzis AJ, Laerum OD, Arnold H, Bjerkvig R. Interactions between fetal rat brain cells and mature brain tissue in vivo and in vitro. Neuropathol Appl Neurobiol 1994; 20:130-43. [PMID: 8072644 DOI: 10.1111/j.1365-2990.1994.tb01172.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Fetal as well as mature neural cells were homografted into the right cerebral hemisphere of adult BD-IX rats. The animals were sacrificed 7 d after implantation, and the localization of implanted cells was visualized by fluorescence and light microscopy. The cell implants were prestained with the fluorescent vital dye 1,1'-Dioctadecyl-3,3,3'3'-tetramethylindocarbocyanine perchlorate (DiI) to discriminate between implanted cells and host brain tissue. At the implantation site, the fetal brain cells as well as the cells from immature brain cell aggregates showed diffuse infiltration into the surrounding host brain tissue of up to 0.5 mm. Extensive cell migration along the corpus callosum for up to 5 mm in the coronal and to a lesser extent in the sagittal plane was also observed. In addition, fetal cells were distributed in the subarachnoid space of both cerebral hemispheres and showed a distinct association with larger blood vessels. Cells from mature brain aggregates did not migrate as far as fetal cells and showed only a local infiltration into the host neuropil. Fluorescent microspheres as well as fixed fetal brain cells were implanted, either alone or in combination with vital cells to distinguish between active cell migration and passive cell displacement. The microspheres and the fixed cells were found either localized to the implantation pathway or distributed in the corpus callosum for up to 2 mm in the coronal plane without any dispersion in the sagittal plane. The microspheres also showed an extensive displacement in the subarachnoid space. In vitro co-culture experiments between two immature aggregates showed a complete fusion of the two aggregates during a 96 h culture period. In co-cultures between two mature aggregates complete fusion was not prominent, although the confrontation zone appeared diffuse. Confrontations between a mature and an immature aggregate showed the same pattern of interaction as seen for the two mature aggregates. It is concluded that carbocyanine dyes may be used as a tracer for transplanted cells. Cells from fetal rat brain cell aggregates, opposed to those from mature aggregates, showed extensive migration along well defined anatomical structures in the mature along well defined anatomical structures in the mature brain. Some of the spread of cells following implantation is probably due to passive movement since inert microspheres will spread into certain areas of the CNS.
Collapse
Affiliation(s)
- K Marienhagen
- Department of Neurosurgery, University of Lübeck, Germany
| | | | | | | | | | | |
Collapse
|
46
|
Pedersen PH, Ness GO, Engebraaten O, Bjerkvig R, Lillehaug JR, Laerum OD. Heterogeneous response to the growth factors [EGF, PDGF (bb), TGF-alpha, bFGF, IL-2] on glioma spheroid growth, migration and invasion. Int J Cancer 1994; 56:255-61. [PMID: 8314309 DOI: 10.1002/ijc.2910560219] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The effects of 5 different growth factors [EGF, PDGF(bb), TGF-alpha, bFGF and IL-2] were studied on tumour spheroids obtained from 5 different human glioma cell lines (U-251MG, D-263MG, D-37MG, D-54MG, GaMG). The expression of EGF and PDGF receptors as well as the endogenous production of TGF-alpha and PDGF were studied by Northern blot analyses. After growth-factor-exposure, tumour spheroid volume growth, and directional cell migration from the spheroids were studied. In addition, tumour-cell invasion was studied in vitro, where foetal rat-brain aggregates were used as a target for the tumour cells. In all the assays a common stimulator for most of the cell lines was EGF. The other growth factors had a more heterogeneous stimulatory effect. Tumour-cell invasion, cell growth and cell migration are biological properties which are not necessarily related to each other. This may explain why the tumours often responded differently to the growth factors in the various assay systems. Two of the cell lines studied were non-invasive (U-251MG, D-263MG). It is shown that these were stimulated both in the directional migration assay and in the spheroid-volume-growth assay. However, their non-invasive behaviour was not influenced by the growth factors studied.
Collapse
Affiliation(s)
- P H Pedersen
- Gade Institute, Department of Pathology, Haukeland Hospital, University of Bergen, Norway
| | | | | | | | | | | |
Collapse
|
47
|
Pedersen PH, Marienhagen K, Mørk S, Bjerkvig R. Migratory pattern of fetal rat brain cells and human glioma cells in the adult rat brain. Cancer Res 1993; 53:5158-65. [PMID: 8221651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The migratory behavior of two human glioma cell lines (D-54MG and GaMG) and fetal rat brain cells grafted into the adult rat brain was studied. To trace the implanted cells, they were stained with the carbocyanine vital dye 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate before injecting them into the white matter above the corpus callosum. The animals were sacrificed 2 h and 7 and 21 days after injection, and the brains were removed and cryosectioned. Fluorescence microscopy showed that both the 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate-stained fetal and tumor cells had the same migratory pattern. Implanted cells were found along myelinated fibers in the corpus callosum and in the perivascular space. After immunostaining for several extracellular matrix (ECM) components (laminin, fibronectin, collagen type IV, and chondroitin sulfate), laminin deposits were observed in the border zone between the host tissue and implanted tumor cells as well as fetal cells. By using two different types of antibodies against fibronectin, it is shown that the fibronectin expression observed in the tumor matrix may be host derived. This was further supported by the fact that tumor spheroids obtained from the two glioma cell lines were negative when immunostained for these ECM components. Several of the ECM components may be host derived. This can be caused by neovascularization and repair synthesis or by a local production of guiding substrates which are important for tumor cell locomotion. The present data suggest that the migratory patterns of fetal and glioma cells are indistinguishable when transplanted into the adult rat brain. Thus, glioma cells may be routed by the same ECM components that play a major role during brain development.
Collapse
Affiliation(s)
- P H Pedersen
- Gade Institute, Department of Pathology, University of Bergen, Haukeland Hospital, Norway
| | | | | | | |
Collapse
|
48
|
Engebraaten O, Bjerkvig R, Pedersen PH, Laerum OD. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer 1993; 53:209-14. [PMID: 8381111 DOI: 10.1002/ijc.2910530206] [Citation(s) in RCA: 136] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Spheroids initiated directly from human primary gliomas were used to investigate the effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferation, migration and invasion into foetal rat brain tissue. EGF increased tumour spheroid volume in 10 of 13 glioblastomas studied, whereas 5 of 11 tumours responded to bFGF. NGF increased the spheroid volume in 2 of 5 tumours. In 8 tumours, PDGF(bb) had no effect on tumour spheroid volume. An increase in BUdR-labelling indices confirmed that cell proliferation was responsible for the volume increase observed in stimulated spheroids. EGF stimulated cell migration in 5 and bFGF in 3 of 8 tumours studied. NGF stimulated cell migration in 1 of 5 glioblastomas, whereas 1 of 3 glioblastomas responded to PDGF(bb). The effects of growth factors on the invasion of spheroids prepared from the glioblastoma biopsy specimens were also studied in vitro using foetal rat brain aggregates as target tissue. EGF stimulated invasion in 7 of 8 glioblastomas studied, whereas bFGF stimulated invasion in 2 of these tumours. NGF or PDGF(bb) did not increase the invasiveness of the glioblastoma tissue. Our results represent the net effect of the growth factors on a complex tumour-cell population. We conclude that exogenously administered growth factors, EGF in particular, increase the cell proliferation as well as migratory and invasive capacities of cultured primary brain tumour biopsies in vitro.
Collapse
Affiliation(s)
- O Engebraaten
- Gade Institute, Department of Pathology, University of Bergen, Norway
| | | | | | | |
Collapse
|
49
|
Wester K, Pedersen PH. Benign Intracerebral Cysts Treated with Internal Shunts. Neurosurgery 1992. [DOI: 10.1097/00006123-199203000-00022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
50
|
Abstract
Two elderly women with symptomatic benign intracerebral cysts are reported. Before treatment, they both had developed moderate, but slowly increasing, symptoms from a cyst in the left hemisphere, which included epileptic seizures and right hemiparesis. During local anesthesia, an internal cystosubarachnoid shunt was inserted. After the operation, the cyst size was reduced markedly, with a corresponding improvement in the symptoms. A review of reported cases of benign intracerebral cysts is given. The average age of these patients is surprisingly high for a presumed congenital condition. There is a female preponderance, but the previously reported overrepresentation of left-sided lesions is not found in cases described after the introduction of computerized tomographic imaging.
Collapse
Affiliation(s)
- K Wester
- Department of Neurosurgery, University of Bergen School of Medicine, Haukeland Hospital, Norway
| | | |
Collapse
|